Literature DB >> 17709233

The radiobiology of Papillon-type treatments.

R G Dale1.   

Abstract

The dominant influence in all types of contact therapy is physical rather than radiobiological in nature and is associated with the rapid fall-off of dose with increasing depth in tissue. Even at a depth of only 20 mm the dose has typically fallen to around 15% of the surface dose, meaning that the deeper (and, potentially, dose-limiting) structures are physically spared. Papillon treatments therefore owe their clinical success largely to this simple characteristic and the radiobiological issues, although of interest, might be dismissed as being of secondary importance. However, consideration of the associated radiobiology is useful as it provides a deeper insight into why Papillon-type treatments are effective and also helps to identify the circumstances in which more careful planning of treatment might be required. Some of the most relevant issues are discussed in this paper. The essential points are introduced in a qualitative manner and then followed by some quantitative assessments.

Mesh:

Year:  2007        PMID: 17709233     DOI: 10.1016/j.clon.2007.07.010

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  2 in total

1.  Dose escalation using contact X-ray brachytherapy (Papillon) for rectal cancer: does it improve the chance of organ preservation?

Authors:  Arthur Sun Myint; Fraser McLean Smith; Simon William Gollins; Helen Wong; Christopher Rao; Karen Whitmarsh; Raj Sripadam; Paul Rooney; Michael Jeremy Hershman; Zsolt Fekete; Kate Perkins; D Mark Pritchard
Journal:  Br J Radiol       Date:  2017-11-10       Impact factor: 3.039

2.  Contact X-ray Brachytherapy for Older or Inoperable Rectal Cancer Patients: Short-Term Oncological and Functional Follow-Up.

Authors:  Petra A Custers; Barbara M Geubels; Inge L Huibregtse; Femke P Peters; Ellen G Engelhardt; Geerard L Beets; Corrie A M Marijnen; Monique E van Leerdam; Baukelien van Triest
Journal:  Cancers (Basel)       Date:  2021-12-16       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.